Filing summary
Important scope note: Although the request identifies Tango Therapeutics, Inc., this is BCTG Acquisition Corp.’s unaudited Form 10-Q for the quarter ended March 31, 2021. Tango is described as the proposed merger target; this filing does not report Tango’s standalone operating results.
Business context and reporting period
BCTG was a blank-check company seeking a business combination, with an intended focus on biotechnology. It reported no operating revenue and said its activity through March 31, 2021 consisted of formation, its 2020 IPO, and seeking and negotiating a business combination. The financial statements cover the three months ended March 31, 2021; the filing does not provide a comparable prior-year quarterly income statement.
Financial position and results
| Metric | Reported amount |
|---|---|
| Operating revenue | None |
| Operating loss | $265,895 |
| Net loss | $239,754 |
| Interest earned on Trust Account investments | $26,666 |
| Cash in operating account, March 31 | $1,258,456 |
| Working capital, March 31 | Approximately $1.2 million |
| Trust Account investments, March 31 | $166,809,388 |
| Total liabilities, March 31 | $6,138,214, including $5,836,250 in deferred underwriting commissions |
| Net cash used in operating activities | $55,629 |
BCTG reported no outstanding Working Capital Loans and no off-balance-sheet arrangements. Its trust assets were invested in short-term U.S. Treasury securities. The filing provides no operating margin measure; margins are not meaningful given the absence of revenue.
Material changes and proposed transaction
On April 13, 2021, after quarter-end, BCTG agreed to combine with Tango. The stated merger consideration was $550 million in BCTG shares, valued at $10 per share. BCTG also entered subscription agreements for a proposed $186.1 million private placement. These transactions were not completed as of the reporting date and remained subject to approvals and other closing conditions.
Compared with December 31, 2020, cash declined from $1,314,085 to $1,258,456, while Trust Account investments were nearly unchanged. Total liabilities increased from $5,950,604 to $6,138,214; the filing does not present a prior-year quarterly operating comparison.
Outlook, risks, and contingencies
- Management said available working capital and borrowing capacity were expected to meet needs through the earlier of a business-combination closing or one year from the filing. The merger agreement restricts BCTG from entering into Working Capital Loan arrangements.
- The proposed transaction required, among other things, stockholder approval, regulatory clearance, at least $5,000,001 of net tangible assets after redemptions, and at least $300 million of net proceeds at closing, subject to specified shortfall provisions. Either party could terminate if closing had not occurred by September 30, 2021, subject to the agreement’s terms.
- If BCTG did not complete a business combination by September 8, 2022, and shareholders did not approve an extension, it was required to wind up and redeem public shares, subject to applicable obligations and law.
- The filing said COVID-19 could adversely affect BCTG’s financial position or transaction efforts, but the specific impact was not determinable.
- The $5.8 million deferred underwriting commission was payable from Trust Account funds only if a business combination was completed.
Key facts investors should verify
- Confirm the intended filing subject: this is BCTG’s SPAC filing, not Tango’s standalone 10-Q.
- Review the merger agreement and subsequent filings for transaction status, final consideration, closing conditions, redemptions, and actual proceeds.
- Verify whether the proposed $186.1 million private placement and the sponsor’s separate share-purchase commitment were funded and on what terms.
- Assess the impact of public-share redemptions on the minimum cash and net tangible asset conditions and on post-transaction ownership.
- Confirm the timing and treatment of deferred underwriting commissions and any material updates to liquidity or transaction risks.